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Background: Patients with stage I testicular seminoma are typically diagnosed at a young age and treatment is associated with
low relapse and mortality rates. The long-term risks of adjuvant radiotherapy in this patient group are therefore particularly
relevant.
Methods: We identified patients and obtained treatment details from 12 cancer centres (11 United Kingdom, 1 Norway) and
ascertained second cancers and mortality through national registries. Data from 2629 seminoma patients treated with
radiotherapy between 1960 and 1992 were available, contributing 51 151 person-years of follow-up.
Results: Four hundred and sixty-eight second cancers (excluding non-melanoma skin cancers) were identified. The standardised
incidence ratio (SIR) was 1.61 (95% confidence interval (CI): 1.47–1.76, Po0.0001). The SIR was 1.53 (95% CI: 1.39–1.68, Po0.0001)
when the 32 second testicular cancers were also excluded. This increase was largely due to an excess risk to organs in the radiation
field; for pelvic–abdominal sites the SIR was 1.62 (95% CI: 1.43–1.83), with no significant elevated risk of cancers in organs
elsewhere. There was no overall increase in mortality with a standardised mortality ratio (SMR) of 1.06 (95% CI: 0.98–1.14), despite
an increase in the cancer-specific mortality (excluding testicular cancer deaths) SMR of 1.46 (95% CI: 1.30–1.65, Po0.0001).
Conclusion: The prognosis of stage I seminoma is excellent and it is important to avoid conferring long-term increased risk of
iatrogenic disease such as radiation-associated second cancers.
Approximately 80% of patients with testicular seminoma
present with stage I disease and the traditional management for
many decades has been orchidectomy followed by adjuvant
radiotherapy to abdominal lymph nodes (Hamilton et al, 1986;
Zagars and Babaian, 1987; Fossa et al, 1989). An overview of 16
series including 2603 patients identified a relapse rate after
radiotherapy of 4.4% and a seminoma mortality rate of
2.1% (Zagars, 1996). As the majority of patients are treated in
young adult life and do not need chemotherapy, they represent a
group in whom the long-term radiotherapy risks are relevant
and are measurable where population health records are
available. Surveillance studies suggest that about 18–20% of
these patients have subclinical abdominal node metastases
(Horwich et al, 1992; von der Maase et al, 1993; Warde et al,
1993) and thus have the potential to gain from adjuvant
radiotherapy. As the great majority of patients are cured, there is
concern over radiation carcinogenesis (van Leeuwen et al, 1993;
Horwich and Bell, 1994; Travis et al, 1997; Richiardi et al, 2007;
Hemminki et al, 2010) and over other possible late radiation effects
(Zagars et al, 2004).
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Previous large cohort studies of long-term cancer risk in
patients cured of testicular cancer have been based mainly on
Cancer Registry cases where diagnostic, staging and treatment data
may be recorded less accurately than in the radiotherapy centre, so
that potential confounding factors such as chemotherapy may be
underestimated, and the extent of radiation fields may not have
been recorded. An exception was the report from Zagars et al
(2004) on 453 patients treated for early-stage seminoma with
radiotherapy at the MD Anderson Cancer Center between 1951
and 1999, which found a life-shortening effect of radiotherapy
when comparing a cured population of seminoma patients with
age-matched male US population. Specific excess mortalities were
found because of second cancers and cardiac disease and appeared
after 15 years of follow-up.
Patients with stage I seminoma represent a group with low
cancer recurrence risk, a long prognosis and a relatively low
exposure to diagnostic ionising radiation, and are thus an ideal
group in which to define the risks of radiotherapy. Following
award of funding from the UK Medical Research Council and
approval from the Royal Marsden Research Ethics Committee
(Protocol No. 1131), we therefore undertook an analysis of second
cancer risks in men with stage I seminoma identified and treated in
1 of 11 radiotherapy centres in the United Kingdom or one in
Norway diagnosed between 1960 and 1992 when management
policies in these centres were stable.
MATERIALS AND METHODS
Two thousand eight hundred and twenty-nine patients were
initially identified (UK 2058, Norway 771). Radiotherapy details
were collected retrospectively from the treating radiotherapy
centre. One hundred patients were excluded on review as they
did not have stage I seminoma (n¼ 73), were duplicates (n¼ 4),
were diagnosed outside the study period (n¼ 12) or had missing/
inconsistent dates of diagnosis, treatment or relapse (n¼ 11)
(Figure 1). Radiotherapy was administered from anterior and
posterior portals with dosage specified at the mid-plane. The most
common doses were 30Gy, or 35/36 or 40Gy given over 3–4
weeks, and for purposes of analysis doses were considered into
three groups relating to these clusters. Overall follow-up was
calculated from the date of diagnosis to death and was censored at
31 December 2007.
Second cancers and deaths were ascertained by matching
patients to national registries. In the United Kingdom, cancers
were coded to ICD10 and in Norway to ICD7 up to 1992 and
ICD10 thereafter. In the United Kingdom, patient details were sent
to the NHS Information Centre’s Medical Research Information
Service for matching to national cancer registry data and ‘flagging’
to provide details of cancer registrations, deaths and other exits
from the NHS system (e.g. emigration). One hundred of the 2031
eligible UK patients could not be traced at the registry. These were
in general born earlier (median 1938 vs 1964 Mann–Whitney test,
P¼ 0.003) and diagnosed earlier (median 1978 vs 1984, Po0.0001)
than the rest of the UK cohort but there was no difference in age at
diagnosis (37.1 vs 36.9, P¼ 0.62). In Norway, the status of all 698
eligible patients to end 2007 was ascertained by the cancer registry.
For each subject, person-years at risk of developing a subsequent
cancer, by 5-year age group and calendar year were estimated.
To exclude potential second cancers missed at diagnosis of the
primary tumour or those not potentially due to radiotherapy
exposure, the at-risk period was deemed to commence 1 year after
the start of radiotherapy. Patients who relapsed, died or were lost
to follow-up at the hospital site before this date are excluded from
all person-years based analyses. All patients were left-censored on 1
January 1971, which is the first date for which UK national cancer
Patients identified from
hospital records
(n=2829)
Eligible-traced patients
(n=2629)
Incorrect diagnosis or completion RT date (n=8)
Not stage I seminoma (n=73)
Duplicates (n=4)
Date of diagnosis < 1960 (n=1)
Date of diagnosis > 1992 (n=11)
Date of diagnos is missing (n=2)
Date of relapse missing (n=1)
Not traced at national registry (n=100)
Analysis cohort
“at risk” of second cancer
(n=2543)
Deaths, relapses or embarkations before
period at risk (n=79)
Patients for whom last available information
was within a year from radiotherapy (n=7)
51 151 person-years at risk
468 second cancers
645 deaths
Figure 1. Cohort summary.
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registration data are available, resulting in a loss of 1195 person-
years of follow-up. Patients were right-censored at known relapse
of germ cell cancer (obtained from hospital records), date of
emigration (from registry) or death. Surviving patients were
censored on 31 December 2007. Risk of solid cancers at common
sites and at sites within/close to the radiation field were explored.
For analyses relating to time since diagnosis of seminoma, subjects
were allocated at each point in their follow-up to the analytic
category applicable for that time.
Expected numbers of deaths and second cancers incident in the
cohort were calculated for each cancer site by multiplying age-,
sex- and calendar year-specific person-years at risk in the cohort by
the corresponding death and cancer registration rates in the
general population of England and Wales (Cancer Registrations
MB1 series, ONS) or Norway (Engholm et al, 2010) as appropriate.
Causes of death were categorised as cancer (ICD10 C00-C97),
diseases of the circulatory system (ICD10 I00-I99), including heart
and cerebrovascular disease, or other.
The ratio of observed to expected numbers of deaths or cancers,
and the standardised incidence/mortality ratios (SIR/SMR) were
then calculated, with likelihood-based 95% confidence intervals
(CIs). All significance levels cited are two-sided. All analyses were
conducted in STATA v.11.2 (StataCorp LP, College Station, TX,
USA).
RESULTS
The eligible cohort comprised 2629 men who had had orchidec-
tomy for stage I seminoma and were then treated at 1 of 12
radiotherapy centres (Figure 1). Median age at diagnosis was 37.2
years (interquartile range 31.3–44.7) and median overall follow-up
was 21.8 years (interquartile range 17.5–27.5 years).
Age and year of diagnosis as well as radiotherapy treatment
details of the analysis cohort (n¼ 2543) are given in Table 1.
Ninety-one per cent (2314) of patients had radiotherapy to
abdominal and pelvic lymph nodes. A further 6.3% (161) had only
para-aortic node radiotherapy and only 1% of the total had any
thoracic or neck irradiation in addition to abdominal fields. Of the
88 eligible patients excluded from the analysis cohort (Figure 1),
41 were diagnosed before 1971.
Table 1. SIR for all cancers excluding non-melanoma skin and testis by age at diagnosis, year of diagnosis, radiotherapy volume, dose and machine
Number of
second
cancers
observeda
(N¼436)
Number of
patients at riska
(N¼2543)
Person-years
at riska,b
(N¼51151)
Median
follow-up
(years)b SIR 95% CI
Age at diagnosis of initial seminoma (years)c
o30 44 509 10 730 21.8 2.90*** 2.16–3.90
30–39 140 1012 21 191 21.9 1.94*** 1.64–2.28
40–49 159 643 13 202 21.3 1.55*** 1.32–1.81
50–59 64 255 4454 19.4 1.05 0.83–1.34
60þ 28 116 1457 14.8 0.90 0.62–1.30
Year of diagnosis of initial seminoma
1960–1965 51 125 2941 32.6 1.71*** 1.30–2.25
1966–1970 60 196 4856 31.1 1.48** 1.15–1.91
1971–1975 61 224 5953 32.5 1.41* 1.10–1.82
1976–1980 95 415 9694 27.7 1.74*** 1.42–2.13
1981–1985 89 603 12 261 23.5 1.45** 1.18–1.79
1986–1990 65 699 11 603 19.0 1.44* 1.13–1.84
1991–1992 15 281 3843 15.9 1.36 0.82–2.26
Treated volume
Para aortic nodes only 10 161 2661 17.3 0.91 0.49–1.69
Para aorticþpelvic nodes±femoral nodes/scrotum 253 1828 35 021 20.4 1.46*** 1.29–1.66
Whole abdomen 164 486 12 064 28.3 1.74*** 1.49–2.02
Mediastium/neck (in addition to any of the above) 4 25 577 26.2 1.46 0.55–3.90
Radiotherapy machine
Linear accelerator 242 1795 33 762 19.8 1.52*** 1.34–1.72
Telecobalt 17 123 2466 21.3 1.15 0.71–1.85
Radiotherapy dose (Gy)d
p31 153 1401 25 265 19.0 1.31** 1.12–1.54
32–38 163 740 16 544 23.8 1.62*** 1.39–1.89
438 116 353 8481 27.6 1.83*** 1.53–2.20
Abbreviations: CI¼ confidence interval; SIR¼ standardised incidence ratios. ***Pp0.0001. **Po0.001. *Po0.01.
aColumn totals within each subgroup variable do not sum to totals due to missing data.
bPerson years is calculated from 1 year after radiotherapy and is left censored on 1 January 1971; median follow-up is calculated from the date of diagnosis.
cTest for trend across groups: Pp0.0001.
dTest for trend across groups: P¼ 0.006.
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During 51151 person-years at risk in 2543 patients, there were
468 second cancers (excluding non-melanoma skin cancers
(NMSCs)) reported in 403 men. Six hundred and forty-five men
were reported to have died, 66 men were censored at relapse and
15 emigrated, leaving 1709 alive without second cancer at the time
of data cutoff.
Overall, the SIR for second cancer incidence (excluding NMSC)
was 1.61 (95% CI: 1.47–1.76, Po0.0001). If second testicular
cancers were also excluded from analysis, the SIR was 1.53 (95%
CI: 1.39–1.68, Po0.0001) giving an absolute excess risk of 29.4
cancers per 10 000 person-years.
The SIR decreased with age at diagnosis (Table 1, test for trend
across five age groups: Po0.0001). There was no obvious
relationship between SIR and attained age. The SIR increased with
time after radiotherapy (Figure 2, trend: Po0.0001); the significant
increased risk is observed 15 years after radiotherapy onwards,
although the apparent greater risk after 35 years is based on small
numbers of men at risk and of events. Analysis of SIR by
radiotherapy treatment variables (Table 2) provided some evidence
of a radiation dose effect (P for trend across three groups¼ 0.006),
with the SIR for o32Gy at 1.31 (1.12–1.54) compared with
the dose range 438Gy at 1.83 (1.53–2.20) giving an IRR of 1.39
(1.10–1.77). Although an increased risk was not shown in the 161
patients whose radiotherapy was confined to a para-aortic field,
the incident number of second cancers and the person-years at risk
were low, generating wide confidence intervals. In addition, para-
aortic fields and lower radiation doses were techniques used in
more recently treated patients, in whom the full second cancer risk
may not yet be fully apparent. The median dose decreased
significantly over year of diagnosis groups from 36Gy between
1960 and 1980 to 34Gy between 1981 and 1985 and 30Gy between
1986 and 1992 (Kruskal–Wallis test with 6 d.f.: Po0.0001); hence,
there is some confounding between dose and duration of follow-
up, although a significant trend in SIR by years at risk was still
seen in an analysis restricted to the subset of 1401 patients
receiving o32Gy.
Risk of specific second cancers are shown in Table 2. There were
significantly elevated risks for bladder cancer (SIR 2.46, 95% CI:
1.86–3.26), pancreatic cancer (SIR 3.14, 95% CI: 2.13–4.60) and
stomach cancer (SIR 1.93, 95% CI: 1.31–2.83). For abdominal
pelvic sites combined, the risk was 1.62 (95% CI: 1.43–1.83). There
was no significant elevated risk of solid cancers in organs outside
the radiation field, for example, lung: SIR 1.21 (95% CI: 0.94–1.55)
and oesophagus: SIR 1.31 (95% CI: 0.71–2.44).
With regard to overall mortality in the cohort, there was no
overall increase compared with age- and sex-matched population
figures with a standardised mortality ratio of 1.06 (95% CI:
0.98–1.14), despite an increase in the cancer-specific mortality. The
SMR for all cancers other than testis cancer was 1.46 (95% CI:
1.30–1.65, Po0.0001), with 264 deaths observed compared with
180 expected, and for circulatory system deaths was 0.80 (95% CI:
0.70–0.92, P¼ 0.002) (Table 3).
DISCUSSION
We have sought to increase the accuracy of risk estimates of the
long-term hazards of adjuvant radiotherapy by analysing a group
treated at young adult age, who would be unlikely to have
confounding risks from either chemotherapy or significant levels of
diagnostic radiation, and in whom initial diagnosis, staging and
treatment details were derived from the radiotherapy centre
directly. These risks have a direct bearing on current management
strategy in stage I seminoma of the testis since adjuvant
radiotherapy is still widely used (Osswald et al, 2009; Vossen
et al, 2012).
We have found that moderate dose infradiaphragmatic RT for
stage I seminoma was associated with an increased risk of
developing a second (non-testicular germ cell) cancer, with an
SIR of 1.53 (95% CI: 1.39–1.68). Increased risks were for organs in
the radiation field. A weakness of our analysis of the impact of
reducing radiation dose and field size is that follow-up was shorter
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Figure 2. Standardised incidence ratio for all cancers excluding non-melanoma skin and testis (with 95% CI) by years at risk.
Second cancer risk and mortality after radiotherapy for seminoma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.551 259
in men with these modifications. There was an associated increased
cancer mortality of the same order of magnitude as the increase in
incidence, but we did not detect an impact of the 264 cancer deaths
(non-testicular) on overall mortality risk when comparing the
cohort of 2543 patients followed for an average of 20.1 years at
risk with matched population figures. This appeared to be due to
a reduced risk of death from circulatory and other non-cancer
causes. We have not determined the reason for this but postulate
a possible impact of health advice such as smoking cessation at
the time of diagnosis of the testicular malignancy. In addition,
since reports both from the United Kingdom and the United
States of America have suggested that testicular cancer has been
more common in higher socioeconomic or higher affluence
groups (Swerdlow et al, 1991; Van den Eeden et al, 1991;
Toledano et al, 2001), it may be that an SMR based on
whole population controls might underestimate an additional
mortality risk from radiotherapy; however, socioeconomic data
on testicular cancer incidence is not available for Norway. It has
been suggested that radiotherapy might increase the risk of a
subsequent cardiac event (Huddart et al, 2003) but recent other
analyses have not confirmed this risk (Van den Belt-Dusebout,
2007; Beard et al, 2013)
Although an increased risk of second cancer is recognised in
patients cured of testicular cancer, neither the baseline risk nor any
increase in this due to either radiotherapy or chemotherapy have
been quantified. An additional weakness of our study is that
ascertainment bias cannot be excluded as the irradiated men would
be likely to remain on medical follow-up for years after treatment.
Table 2. SIRs for common cancers sites and cancer sites within the radiation field
Site
Second cancers
observed Second cancers expected SIR 95% CI
All (excl non-melanoma skin) 468 291.6 1.61*** 1.47–1.78
Testis 32 3.4 9.45*** 6.68–13.36
All non-testisa 436 285.4 1.53*** 1.39–1.68
Prostate 80 60.3 1.33* 1.07–1.65
Colorectal 55 41.6 1.32* 1.02–1.72
Colon 30 23.8 1.26 0.88–1.80
Rectum (and anus) 25 18.0 1.39 0.94–2.05
Bladderb 49 19.9 2.46*** 1.86–3.25
Bladder and ureter/renal pelvisb 53 20.4 2.60 *** 1.99–3.40
Pancreas 26 8.3 3.14*** 2.13–4.60
Stomach 26 13.5 1.93** 1.31–2.83
Kidney 8 8.9 0.90 0.45–1.80
Liver 2 2.7 0.75 0.19–3.00
Penis 2 1.0 1.96 0.49–7.82
Abdopelvicc 252 155.7 1.62*** 1.43–1.83
Lung 61 50.5 1.21 0.94–1.55
Melanoma 15 9.9 1.52 0.91–2.51
Oesophagus 10 7.6 1.31 0.71–2.44
Leukaemiad 9 5.11 1.76 0.92–3.38
Soft tissuee 4 1.6 2.53 0.95–6.75
Abbreviations: CI¼ confidence interval; SIR¼ standardised incidence ratios. ***Po0.0001. **Po0.01. *Po0.05. Figures in bold type for totals and subtotals.
aOther cancers diagnosed but not listed elsewhere on table include: brain and CNS (n¼ 12); lymphomas (10); head and neck (8); larynx (5); other respiratory/intrathoracic (5); mesothelioma (3);
peritoneum (3); thyroid (2); small intestine (2); other/unspecified biliary tract (2); bone (1); eye (1); secondary cancers (17); other/ill-defined sites (8); unspecified/not known (6).
bIn ICD7 (to which Norwegian data were coded), bladder cancer (ICD7 181) included cancers of the ureter and renal pelvis. Data from England and Wales were coded to ICD9 and ICD10 in
which these cancer sites are separately coded.
cIncludes all sites in the abdominal–pelvic region listed above.
dUK data only because of difficulties mapping ICD7 coding.
eICD7 197; ICD9 171 and 176.1; ICD10 C49 and C46.1.
Table 3. Standardised mortality ratios
Cause of death Observed deaths Expected deaths SMR 95% CI
All causes 645 610.0 1.06 0.98–1.14
All cancers 292 180.7 1.62*** 1.44–1.81
Circulatory system 206 255.9 0.80** 0.70–0.92
Other non-cancer 147 173.4 0.85* 0.72–1.00
Abbreviations: CI¼ confidence interval; SMR¼ standardised mortality ratios. ***Po0.0001. **Po0.01. *Po0.05.
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The suspicion that radiotherapy may be causal is strengthened by
the particular organ sites of increased risk in relation to the
radiation field. Analysis of a southeast England population
included 5555 patients with seminoma and found they had excess
risks of colon, pancreas, bladder and soft-tissue cancers, as well as
leukaemia (Robinson et al, 2007). Studies of testicular cancer
survivors suggest an overall relative risk increase of 1.4–2.8
compared with population controls (Fung et al, 2012). Travis et al
(2005) reported a large population-based study from 14 Tumour
Registries in Europe and North America, analysing the risks of
second cancers in 40 576 testicular cancer survivors. They
demonstrated a cumulative risk of 36% by the age of 75 years
for patients diagnosed with seminoma at 35 years of age and 31%
for a diagnosis of NSGCT compared with 23% for the matched
general population. There was an association between the relative
risk for secondary malignancy and time since diagnosis. For those
more than 10 years from radiotherapy alone the relative risk was
2.0 (95% CI: 1.9–2.2). Infradiaphragmatic radiotherapy was
associated particularly with increased risk of in-field tumours.
Similarly, in a nationwide cohort of testicular cancers from The
Netherlands, subdiaphragmatic radiotherapy was associated with a
2.6-fold increase in second cancers (van den Belt-Dusebout et al,
2007), whereas there were no significant excesses in patients
treated only by surgery. Only limited numbers of patients with
seminoma treated by surgery alone and then surveillance have been
analysed for second malignancy risk, and when sufficient have
been followed for a long period, these will form an good control
group to help quantify treatment effects.
There is therefore concern that the increased risk of developing
second cancer following adjuvant radiotherapy appears roughly
equivalent to the probability of preventing seminoma recurrence in
young men with stage I seminoma, especially as there are
alternatives to adjuvant radiotherapy, as discussed below. As about
one in four men in Western societies will develop cancer (other
than non-NMSC), as a rough approximation (ignoring competing
risks) our relative risk figures suggest a lifetime increase in
cumulative risk of second cancer from 25 to 37%. These estimates
are similar to the increased incidence figures reported by Travis
et al (2005).
Radiotherapy techniques in testicular seminoma have been
modified as the men in this cohort were treated, cutting both dose
and volume to reduce toxicity, and changes have been tested in
randomised trials to confirm no loss of efficacy (Fossa et al, 1999;
Jones et al, 2005). These demonstrated the effectiveness of
restricting the field to just the para-aortic region, and of reducing
the dose to 20Gy. A report from the German Testicular Cancer
Study Group on 721 men treated to the para-aortic region to a dose
of 26Gy indicated a 95.8% (95% CI: 94.2–97.4) 5-year disease-free
survival (Classen et al, 2004). There is some evidence, based on an
analysis of both Hodgkin’s lymphoma and testicular cancers, that
second cancer risks can be reduced by limiting the mean organ
radiation dose (van den Belt-Dusebout et al, 2009). It is likely that
risk for secondary cancers due to current radiotherapy will be
lower than that identified in our analysis, but not eliminated
completely (Zwahlen et al, 2008), but as the reduced dose trial was
only published as recently as 2005, longer follow-up will be needed
to quantify any benefit.
There are alternatives to radiotherapy in the management of
stage I seminoma postorchidectomy. These include surveillance,
a policy that reserves further treatment for those who relapse, or
the use of adjuvant chemotherapy rather than radiotherapy. With
surveillance in unselected patients about 15–20% will have
recurrent disease, very predominantly in para-aortic lymph nodes,
and virtually all recurrences are treated successfully (Warde et al,
2002; Daugaard et al, 2003; Martin et al, 2006; Cummins et al,
2010). Single-agent carboplatin has been evaluated as adjuvant
treatment postorchidectomy. A large multicentre randomised trial
in 1447 men followed for a median of 6.5 years (Oliver et al, 2011)
compared with adjuvant radiotherapy with a single dose of
carboplatin at a dose calculated to achieve an area under the
concentration time curve of 7mgml 1min. Relapse-free rates
at 5 years were 94.7% for carboplatin (96.1% for those treated with
the recommended dose) vs 96.0% for radiotherapy. Early results
suggest that adjuvant carboplatin offers a high cure rate and little
toxicity (Powles et al, 2008; Oliver et al, 2011). However, some
regard the data supporting the adjuvant carboplatin option to be as
yet too preliminary (Bosl and Patil, 2011).
The Swedish Norwegian Testicular Cancer Study Group
undertook a prospective observational study between 2000 and
2006 in stage I seminoma (Tandstad et al, 2011), initially with
options of either adjuvant radiotherapy to a dose of 25.2 Gy in 14
fractions, or with surveillance; subsequently, after 2003, adjuvant
carboplatin (one cycle) was an alternative adjuvant treatment.
There was a 14.3% relapse rate in the 512 patients on surveillance;
retreatment was mainly with combination chemotherapy and there
was only one second relapse. Two patients died, one was
treatment-related and one was coincidental. Of the 481 patients
treated with adjuvant RT, 4 (0.8%) relapsed at a median of 1.1
years, and 1 has needed treatment for a second relapse. Of 188
patients treated with adjuvant carboplatin, 7 (3.9%) relapsed at a
median of 1.8 years; all seven were treated with etoposide/
cisplatinum and there had not been any further relapse at the time
of analysis.
A selective approach based on risk factors (Warde et al, 2002)
with either surveillance for low-risk patients or with adjuvant
carboplatin for higher risk patients has also been evaluated. For
example, the Spanish Germ Cell Cooperative Group have
reported a trial in 227 patients with stage I seminoma followed
for a median of 34 months (Aparicio et al, 2011), in which 19%
had tumours larger than 4 cm, 11% had rete testis involvement
and a further 33% had both these risk factors. Those 74 with two
risk factors received two cycles of adjuvant carboplatin, and only
one relapsed. The remainder were managed by surveillance and
15 (9.8%) relapsed. Follow-up in this study is still short, and the
specific prognostic model has not been validated (Chung et al,
2010).
In conclusion, the overall cure rate in patients with stage I
seminoma is very high whether initial management postorchi-
dectomy is by surveillance or by adjuvant radiotherapy or by
adjuvant carboplatin. Thus, it is important and feasible to seek to
avoid conferring a long-term increased risk of iatrogenic disease
such as radiation-associated second cancers.
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